Author: NSV
FDA Approves Next-Generation ZOLL® TherOx System for Widowmaker Heart Attack Patients First
View Full Press Release >>
Read MoreScripps La Jolla First In U.S. To Use ZOLL’s FDA-Approved SuperSaturated Oxygen Therapy On Patients Suffering from Widowmaker Heart Attacks
View Full Press Release >>
Read More
NorthSea Therapeutics Announces US $40 Million Series B Financing to Complete Phase IIb ICONA study in NASH and to Advance Two Additional SEFAs into the Clinic
Two new US investors; lead investor, venBio Partners and Sofinnova Investments, join syndicate of existing investors Richard Gaster, M.D., Ph.D., Principal at venBio Partners, and Maha Katabi, Ph.D., CFA, Partner at Sofinnova Investments join the Board Proceeds will be used to progress the SEFA development pipeline: Completion of Phase 2b
Read More
EXTEN Technologies and AIC to Provide NVMe-oF Storage Solutions Optimized for Supercomputing
AIC Shark Ultra-High-Performance Storage Target Delivers 80GB/S of Random IOPs in 2U with EXTEN NVMe-oF HyperDynamic Software Austin, November 14, 2019 – AIC and EXTEN® Technologies have partnered to provide a dense and scalable, software-defined NVMe-oF solution with record-breaking performance, advanced management, provisioning, and RAID data protection services. This disaggregated
Read MoreNST doses first patient in Phase 2b clinical study of icosabutate in NASH (‘ICONA’)
Naarden, The Netherlands, 25 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH (Non-alcoholic Steatohepatitis) and other metabolic, inflammatory and fibrotic diseases, today announces dosing of the first patient with icosabutate in a phase 2b dose ranging study (‘ICONA’).
Read MoreNorthSea Therapeutics strengthens its management team with the appointment of Mats Blom as CFO
Naarden, The Netherlands, 4 September 2019 – NorthSea Therapeutics B.V., (‘NST’) a Dutch biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic, inflammatory and fibrotic diseases, today announces the appointment of Mats Blom as Chief Financial Officer (CFO). Mr Blom joined NorthSea Therapeutics on 3
Read MoreEXTEN® Technologies Wins Flash Memory Summit 2019 Best of Show Award for Most Innovative Enterprise Business Application
Second consecutive Best of Show win for EXTEN Technologies demonstrates the leadership position of its HyperDynamic® storage software Santa Clara, CA, August 8, 2019 –EXTEN Technologies®, Inc. announced that its HyperDynamic NVMe over Fabrics high performance storage software won the Best of Show Business Application Award at the 2019 Flash Memory
Read MoreEXTEN® Technologies Announces Version 3.0 of its HyperDynamic® NVMe over Fabrics Storage Software with Enhanced High-Performance Resiliency Features
Austin, TX, August 1, 2019 –EXTEN Technologies®, Inc. announced the availability of the third generation of its award winning HyperDynamic® storage software that brings advanced levels of resiliency, performance and management to demanding data center customers across the globe. EXTEN software is perfect for the extreme levels of performance required by
Read MoreAIC and EXTEN Technologies to Provide NVMe-oF Storage Solutions with the Same Ultra-high Performance as Direct Connected NVMe
Taipei, Taiwan, May 23, 2019 – AIC and EXTEN Technologies have partnered to provide a complete NVMe-oF target solution using a cost-effective FBOF platform running Broadcom PS1100R Stingray 100G SmartNIC with EXTEN HyperDynamic Software. The AIC J2024-04 platform supports twice the PCIe bandwidth of a typical 2U server, allowing quad
Read MoreTherOx Receives FDA Approval for the First Heart Attack Treatment Since PCI to Reduce Infarct Size
View Full Press Release >>
Read More
Oppilan Pharma Initiates Phase 1 Clinical Study with OPL-002
A novel S1P1 modulator for the treatment of inflammatory bowel disease ENCINITAS, California and Cambridge, United Kingdom, January 7, 2019 – Oppilan Pharma Ltd, a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases, today announced that it has completed dosing of the
Read More